OBI Pharma (4174) - Total Liabilities

Latest as of September 2025: NT$748.70 Million TWD ≈ $23.59 Million USD

Based on the latest financial reports, OBI Pharma (4174) has total liabilities worth NT$748.70 Million TWD (≈ $23.59 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

OBI Pharma - Total Liabilities Trend (2011–2024)

This chart illustrates how OBI Pharma's total liabilities have evolved over time, based on quarterly financial data. See 4174 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

OBI Pharma Competitors by Total Liabilities

The table below lists competitors of OBI Pharma ranked by their total liabilities.

Company	Country	Total Liabilities
Stel Holdings Limited NSE:STEL	India	Rs1.04 Billion
HyVision System. Inc KQ:126700	Korea	₩50.51 Billion
Gabelli Global Utility & Income Tr NYSE MKT:GLU	USA	$291.78K
Supercomnet Technologies Bhd KLSE:0001	Malaysia	RM21.42 Million
INNATE PHARMA SP.ADR/1 F:IDDA	Germany	€84.42 Million
Leap Therapeutics Inc NASDAQ:LPTX	USA	$8.70 Million
Norsk Titanium AS OL:NTI	Norway	Nkr14.08 Million
Energoaqua a.s. PR:ENRGA	Czech Republic	Kč791.48 Million

Liability Composition Analysis (2011–2024)

This chart breaks down OBI Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4174 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	5.11	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.34	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.20	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how OBI Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for OBI Pharma (2011–2024)

The table below shows the annual total liabilities of OBI Pharma from 2011 to 2024.

Year	Total Liabilities	Change
2024-12-31	NT$833.38 Million ≈ $26.26 Million	+28.12%
2023-12-31	NT$650.45 Million ≈ $20.49 Million	+30.73%
2022-12-31	NT$497.57 Million ≈ $15.68 Million	-19.22%
2021-12-31	NT$615.95 Million ≈ $19.41 Million	+22.68%
2020-12-31	NT$502.09 Million ≈ $15.82 Million	+9.35%
2019-12-31	NT$459.14 Million ≈ $14.47 Million	+94.53%
2018-12-31	NT$236.03 Million ≈ $7.44 Million	+82.04%
2017-12-31	NT$129.66 Million ≈ $4.08 Million	-22.51%
2016-12-31	NT$167.32 Million ≈ $5.27 Million	+31.74%
2015-12-31	NT$127.00 Million ≈ $4.00 Million	+187.09%
2014-12-31	NT$44.24 Million ≈ $1.39 Million	+6.71%
2013-12-31	NT$41.46 Million ≈ $1.31 Million	-6.63%
2012-12-31	NT$44.40 Million ≈ $1.40 Million	+211.09%
2011-12-31	NT$14.27 Million ≈ $449.68K	--

About OBI Pharma

TWO:4174 Taiwan Biotechnology

Market Cap

$116.20 Million

NT$3.69 Billion TWD

Market Cap Rank

#18718 Global

#1035 in Taiwan

Share Price

NT$28.05

Change (1 day)

+0.72%

52-Week Range

NT$23.25 - NT$50.50

All Time High

NT$743.00